艾司林科

Aisilinco is a Beijing-based biotechnology company specializing in the discovery and development of innovative peptide therapeutics for metabolic and chronic diseases. The company leverages a proprietary high-throughput macrocyclic peptide screening platform to identify high-affinity candidates for challenging biological targets that are often difficult to address with small molecules. Its primary research focus lies in metabolic health, specifically targeting obesity and type 2 diabetes through multi-target agonists. The pipeline includes dual and triple agonists targeting the GLP-1, GIP, and glucagon receptors, designed to provide superior efficacy in weight loss and glycemic control. By integrating advanced chemical biology with peptide engineering, Aisilinco aims to optimize the metabolic stability and delivery of its therapeutic leads. The company is backed by prominent venture capital firms and is actively advancing its lead programs toward clinical trials.